Emergent Health Executes Term Sheet and Engagement Letter with Boustead Securities to roll up its Subsidiary, Evolutionary Biologics and other regenerative medicine and products companies
New York, NY
|
May 18, 2023 09:00 AM Eastern Daylight Time
Emergent Health Corp. (OTC: EMGE), a curator, developer, and marketer of products in the Regenerative Health Space announced that it has executed a Term Sheet and Engagement Letter with Boustead Securities to roll up its subsidiary Evolutionary Biologics and other regenerative medicine and regenerative biologic products companies with NO DILUTION to the Emergent Shareholders with a planned $10 million initial capital raise and public offering and application for listing on NASDAQ or NYSE/AMEX. Emergent’s subsidiary, Evolutionary Biologics, and the new brand called Maximus Men’s Health, along with Juventix Regenerative Medical and Interactive Practice Solutions and Nanosthetic.
Subsequent to the IPO, Emergent plans to distribute the shares received by Emergent from the sale of Evolutionary Biologics as a dividend to its shareholders, pro rata at NO COST to the Emergent Shareholders. Such a dividend would only occur after Emergent files a Registration Statement with the SEC and it is declared effective. Any potential taxable event resulting from such a dividend would be the responsibility of each individual shareholder, and Emergent advises each shareholder to consult with their professional advisors, and makes no representation as to the taxable or nontaxable event. Evolutionary Biologics, is a new kind of biologics company founded for a clear purpose: bring cutting edge regenerative products to the medical community. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease.
Jim Morrison, former L'Oréal President and Emergent’s full time CEO stated, “Boustead Securities is a world class financial organization. They approached us to participate in rolling up a series of regenerative biologics into a brand-new IPO. When you look at the effect that this transaction, and the previously announced PharmaZu transaction, will have on EMGE, it's amazing. We see this as a great way to maximize valuation for our Company and take EMGE to the next level.”
ABOUT EMERGENT HEALTH CORPORATION
Emergent curates, develops and sells products in the Regenerative Health Space. Its products comprise of ingestibles as well as topicals for the whole family. The company distributes its products online and through Content Based Shopping using Influencers to position products in their produced content throughout the United States and Internationally. Its subsidiaries; PharmaZu, is a pure play, e-commerce products and service provider focused on the Pet Community, Pet Pharmacy and Pet Wellness using Influencers and their content, including the pet pharmacy, vet telehealth and pet wellness businesses. Evolutionary Biologics, is a new kind of biologics company founded for a clear purpose: bring cutting edge regenerative products to the medical community. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease. For more information, please visit Emergent's Website and Social Media on Twitter.
Before using any products, you should always consult with your Veterinarian and/or Family Doctor.
SAFE HARBOR STATEMENT
This press release contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
FOR MORE INFORMATION, PLEASE CONTACT:
Jim Morrison, CEO
Emergent Health Corporation Website
info@emergenthealthcompany.com
Contact Details
Emergent Health Corp.
info@emergenthealthcompany.com
Company Website
